SN-38

Name: SN-38
Brand: Selleck Chemicals
SKU: S4908
Rating: 5 (35 reviews)

For research use only.

Catalog No.S4908 Synonyms: NK012

35 publications

CAS No. 86639-52-3

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

Selleck's SN-38 has been cited by 35 publications

Cell Death Differ, 2021, 10.1038/s41418-021-00827-7

PubMed: 34215846 ( click the link to review the publication )

J Exp Clin Cancer Res, 2021, 40(1):15

PubMed: 33407715 ( click the link to review the publication )

Invest New Drugs, 2021, 10.1007/s10637-020-01003-3

PubMed: 33475937 ( click the link to review the publication )

Mutagenesis, 2021, geab014

PubMed: 33964157 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00511-5

PubMed: 33677798 ( click the link to review the publication )

Adv Sci (Weinh), 2020, 7(21):2001018

PubMed: 33173725 ( click the link to review the publication )

Small, 2020, 10.1002/smll.201906360

PubMed: 31972070 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33393

PubMed: 33186476 ( click the link to review the publication )

Cell Death Dis, 2020, 11(9):773

PubMed: 32943619 ( click the link to review the publication )

Oncogenesis, 2020, 9(9):80

PubMed: 32908120 ( click the link to review the publication )

Invest New Drugs, 2020, 10.1007/s10637-020-01014-0

PubMed: 32981006 ( click the link to review the publication )

J Pharm Biomed Anal, 2020, 20;181:113073

PubMed: 31927166 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(7):2120-2127

PubMed: 32775005 ( click the link to review the publication )

Pharmacol Res, 2019, 148:104368

PubMed: 31415918 ( click the link to review the publication )

PLoS One, 2019, 14(10):e0224253

PubMed: 31648230 ( click the link to review the publication )

Cell Mol Gastroenterol Hepatol, 2019, 7(4):819-839

PubMed: 30831321 ( click the link to review the publication )

Oncotarget, 2019, 10(60):6403-6417

PubMed: 31741706 ( click the link to review the publication )

J Control Release, 2018, 275:85-91

PubMed: 29421609 ( click the link to review the publication )

Sci Signal, 2018, 11(540)eaat0229

PubMed: 30042127 ( click the link to review the publication )

Sci Rep, 2018, 8(1):15410

PubMed: 30337664 ( click the link to review the publication )

J Asian Nat Prod Res, 2018, 20(8):781-792

PubMed: 28679068 ( click the link to review the publication )

EMBO Mol Med, 2017, 9(3):293-303

PubMed: 28100566 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(22):6875-6887

PubMed: 28830922 ( click the link to review the publication )

Cancer Lett, 2017, 411:35-43

PubMed: 28964784 ( click the link to review the publication )
Free Radic Biol Med, 2017, 104:280-297

PubMed: 28131902 ( click the link to review the publication )

Cell Death Dis, 2017, 8(10):e3062

PubMed: 28981092 ( click the link to review the publication )

Biochem Pharmacol, 2017, 146:53-62

PubMed: 29031818 ( click the link to review the publication )

Int J Mol Med, 2017, 39(1):217-222

PubMed: 27878250 ( click the link to review the publication )

J Pediatr Hematol Oncol, 2017, 39(5):395-401

PubMed: 28562516 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37394-37408

PubMed: 28445124 ( click the link to review the publication )

Assay Drug Dev Technol, 2016, 14(7):395-406

PubMed: 27552144 ( click the link to review the publication )

J Am Soc Mass Spectrom, 2015, 26(4):577-86

PubMed: 25604392 ( click the link to review the publication )

J Am Soc Mass Spectrom, 2015, 26(4):577-86

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(11):e0142704

PubMed: 26571493 ( click the link to review the publication )

J Pharmacol Exp Ther, 2014, 348(3):432-41

PubMed: 24361696 ( click the link to review the publication )

Purity & Quality Control

Choose Selective ADC Cytotoxin Inhibitors

Biological Activity

Description

SN-38 (NK012) is an active metabolite of CPT-11, inhibits DNA topoisomerase I, DNA synthesis and causes frequent DNA single-strand breaks. SN-38 induces autophagy.

Targets

Topo I ^[1]
(Cell-free assay)

In vitro

SN-38, a biological active metabolite of irinotecan hydrochloride (CPT-11). SN-38 causes the strongest inhibition of DNA topoisomerase I, followed by CPT and then CPT-11. CPT-11 dose dependently shifts the position of relaxed DNA in the direction of nicked DNA, but SN-38 and CPT shows no effect on the position of relaxed DNA. SN-38 dose-dependently and time-dependently inhibit DNA synthesis. Respective IC50 values of SN-38, in DNA synthesis is 0.077 μM. The inhibitory effect of SN-38 on RNA synthesis is less than that on DNA synthesis and it does not inhibit protein synthesis. SN-38 caused frequent DNA single-strand breaks in P388 cells. ^[1]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
human DU145 prostate cell line	MkTIVJJwdGmoZYLheIlwdiCjc4PhfS=>			MV7BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JJBzd3O2YYTlJINmdGxibHnu[UwhUUN3ME2xN{BvVQ>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OEKxOkc,OTB2OUiyNVY9N2F-
human MCF-7 breast cell line	NYGwXVRuWHKxbHnm[ZJifGmxbjDhd5NigQ>?			M{ewRWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGMVch[nKnYYP0JINmdGxibHnu[UwhUUN3ME2wMlM4KM7:TR?=	Ml3YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human SKOV-3 ovarian cell line	NFjLVm5Rem:uaX\ldoF1cW:wIHHzd4F6			NWrsc4NFSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDTT29XNTNib4\hdolidiClZXzsJIxqdmVuIFnDOVA:OC55MjFOwG0>	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODR7OEKxOkc,OTB2OUiyNVY9N2F-
human breast cancer cell line (SK-BR-3)	NIHtUHREgXSxdH;4bYPDqGG\|c3H5			MWXJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHygcIlv\SBqU1utRnIuOyluIFnDOVA:PCCwTR?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN\|NEW2PUc,OTF\|M{S1Olk9N2F-
human lung cancer cell line (H128)	NHLE[XlEgXSxdH;4bYPDqGG\|c3H5			M3Ttc2lvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHygcIlv\SBqSEGyPEktKEmFNUC9OkBvVQ>?	MWq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTN\|NEW2PUc,OTF\|M{S1Olk9N2F-
human stomach cancer cell line (MKN45)	NHjkfHhEgXSxdH;4bYPDqGG\|c3H5			MkLGTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gd5RwdWGlaDDjZY5k\XJiY3XscEBtcW6nIDjNT241PSluIFnDOVA:QCCwTR?=	NUn0U5ZxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN\|Q2PjlpPkGxN\|M1PTZ7PD;hQi=>
human ovarian cancer cell line (SK-OV-3)	MWHDfZRwfG:6aXRCpIF{e2G7			MY\JckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsJIxqdmViKGPLMW9XNTNrLDDJR\|UxRTFzIH7N	NHvuXog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN\|Q2Pjl:L3G+
human colon cancer cell line (WiDr)	NWOwfWF[S3m2b4TvfIlkyqCjc4PhfS=>			MmjJTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHygcIlv\SBqV3nEdkktKEmFNUC9NVQhdk1?	M1TKNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human lung cancer cell line (A549)	M4fX[2N6fG:2b4jpZ:Kh[XO\|YYm=			MV7JckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDseY5oKGOjbnPldkBk\WyuIHzpcoUhMEF3NEmp	NV;XVFZDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN\|Q2PjlpPkGxN\|M1PTZ7PD;hQi=>
NSCLC-H460	NIHQ[HBEgXSxdH;4bYPDqGG\|c3H5			NHf0TYdEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBvd25vc33hcIwu[2WubDDseY5oKGOjcnPpco9u[SClZXzsJIxqdmViSES2NEApVlOFTFOtTFQ3OCluIFnDOVA:QDBibl2=	MoLyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF3NkO5NlUoRjFzNU[zPVI2RC:jPh?=
PC-3 carcinoma cell line	NEnwbZpIem:5dHigbY5pcWKrdHnvckBie3OjeR?=			MXrDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRiZ4Lve5RpKG:oIHj1cYFvKHC{b4P0ZZRmKFCFLUOgZ4Fz[2mwb33hJINmdGxibHnu[UwhUUN3ME2zOU43KG6P	NGrpXlg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUS1OFI{OCd-MUW0OVQzOzB:L3G+
human HCT116 colon cancer cell line	NEHHdXFHfW6ldHnvckBie3OjeR?=			MoPhTY5pcWKrdH;yfUBkd26lZX70doF1cW:wIHHnZYlve3RiaIXtZY4hUEOWMUG2JINwdG:wIHPhcoNmeiClZXzsJIxqdmVuIFnDOVA:PyCwTR?=	MmnrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6MEi0OVYoRjF3OEC4OFU3RC:jPh?=
human Bel-7402 liver cancer cell line	NH35NlZHfW6ldHnvckBie3OjeR?=			MWTJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqdX3hckBD\WxvN{SwNkBtcX[ncjDjZY5k\XJiY3XscEBtcW6nLDDJR\|UxRTNwMUmg{txO	NV35b3M4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW4NFg1PTZpPkG1PFA5PDV4PD;hQi=>
human tumor HL60 cell-line	NGjueVFHfW6ldHnvckBie3OjeR?=		MVOzJIRigXN?	NWLHVopwUW5vdnn0do8hcW6qaXLpeI9zgSClb37j[Y51emG2aX;uJIZweiCqdX3hckB1fW2xcjDIUFYxKGOnbHytcIlv\SC5YYOg[IV1\XKvaX7l[EB2e2mwZzDTVmIh[XO\|YYmgZYZ1\XJiMzDkZZl{KG:oIHnuZ5Vj[XSrb36sJGlEPTB;MUmgcm0>	MmjqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV7MUO5PVYoRjF3OUGzPVk3RC:jPh?=
human H460 cell	Mm[yS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl?			M{nLTGlvcGmkaYTpc44hd2ZiaIXtZY4hUDR4MDDj[YxtKGe{b4f0bEwhUUN3ME24NEBvVQ>?	NUPWeVAxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[5NVM4ODZpPkG2PVE{PzB4PD;hQi=>
MDA-MB-435	MUHGeY5kfGmxbjDhd5NigQ>?			M{n4fmlvcGmkaYTpc44h[WejaX7zeEBOTEFvTVKtOFM2KFNiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCrbjD0bIUh[WK\|ZX7j[UBw\iCjbHL1cYlvNCCLQ{WwJF0hOC5yMEWg{txONg>?	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB3MkiwNkc,OTFyNUK4NFI9N2F-
MDA-MB-435	M2rndWZ2dmO2aX;uJIF{e2G7			NFS4OFhKdmirYnn0bY9vKGGpYXnud5QhVUSDLV3CMVQ{PSCVIHj1cYFvKGK{ZXHzeEBk[W6lZYKgZ4VtdHNiaX6geIhmKHC{ZYPlcoNmKG:oIEOwJI1oN22OIFjTRUwhUUN3MDC9JFAvODVizszNMi=>	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTB3MkiwNkc,OTFyNUK4NFI9N2F-
PC-6/SN2-5H	NYTmcmVbTnWwY4Tpc44h[XO\|YYm=			M37CR3RRZ1SUQV7TVG9TXEWUOjD1dJRic2ViaX6gcYVu[nKjbnWgeoV{cWOuZTDmdo9uKFCFLU[vV24zNTWKIHPlcIx{NCCNbTC9JFQh\|ryPLh?=	M1G1elxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzNki4PVgzLz5zMU[4PFk5OjxxYU6=
HT-29	M{XLfGZ2dmO2aX;uJIF{e2G7			M4XEfmlvKH[rdILvJIlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDy[ZF2cXKnZDDh[4FqdnO2IFjUMVI6KGi3bXHuJINwdG:wIHPhcoNmeiClZXzsd{whUUN3MDC9JFAvODJ5MzFOwG0v	Mkj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTJ4MUe5NlcoRjF{NkG3PVI4RC:jPh?=
SaoS2	NHnOTZFHfW6ldHnvckBie3OjeR?=			NYDYWYFiXFChVGLBUnNRV1KWRWK6JIRzfWdicnXzbZN1[W6lZTjJcYF1cW6rYjDt[ZN6dGG2ZTmgbY4hSkOUUD3lfJBz\XO\|aX7nJHNid1N{IHPlcIx{NCCLQ{WwJF0hOC5zN{[g{txONg>?	NF3ucWM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUC1PVg5OSd-MUWwOVk5QDF:L3G+
DU145	NIS2dVJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MXi5OkBpenN?	MX;BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKESXMUS1JINmdGy\|IHHmeIVzKDl4IHjyd{whUUN3MDC9JFAvODB2IN88UU4>	NGXkXVI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3OlE1OSd-MUiyO\|YyPDF:L3G+
MIA PaCa	NY\QV41PSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MVi5OkBpenN?	MWPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2LQTDQZWNiKGOnbHzzJIFnfGW{IEm2JIhzeyxiSVO1NEA:KDBwMEC2JO69VS5?	M{HHVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
HT29	NYe1UZY1SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MmrYPVYhcHK\|	M3i2VGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiB7NjDodpMtKEmFNUCgQUAxNjBzMjFOwG0v	M3LhT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Mke2NVQyLz5zOEK3OlE1OTxxYU6=
H460	NIO4VWpCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NETPOosyKGi{	NFzR[pdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOgZYZ1\XJiMTDodkBw\iCmcoXnJIV5eG:\|dYLlJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyxiSVO1NEA:KDBwMkKg{txONg>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDR{NEGzN{c,OTh2MkSxN\|M9N2F-
HT29	Ml65RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MWixJIhz	MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiYX\0[ZIhOSCqcjDv[kBlenWpIHX4dI9{fXKnIH3lZZN2emWmIHHmeIVzKDd{IHjyd{whUUN3MDC9JFAvPjdizszNMi=>	NF\xO2Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOESyOFE{Oyd-MUi0NlQyOzN:L3G+
HT29	MkexRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NWLUUGpLOSCqch?=	MnPLRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDCR3JRKG:4ZYLlfJBz\XO\|aX7nJI1qfG:6YX70do9v\S2{ZYPpd5RidnRiaIXtZY4hUFR{OTDj[YxteyCjZoTldkAyKGi{IH;mJIRzfWdiZYjwc5N2emVibXXhd5Vz\WRiYX\0[ZIhPzJiaILzMEBKSzVyIE2gNVEvPSEQvF2u	M1LUU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEK0NVM{Lz5zOESyOFE{OzxxYU6=
H460	MlnaR5l1d3SxeHnjbZR6KGG\|c3H5			M3rafmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg1PjBiY3XscJMtKEmFNUCgQUAxNjJ{IN88UU4>	NV62SHZ5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0N\|QyPTNpPkG4OFM1OTV\|PD;hQi=>
A549	M1LsW2N6fG:2b4jpZ4l1gSCjc4PhfS=>			NUPFcXM2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCkeTDTVmIhdWW2aH;kMEBKSzVyIE2gNE4xQCEQvF2u	Ml7QQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7OE[4NFcoRjF6OUi2PFA4RC:jPh?=
HT-29	MY\DfZRwfG:6aXPpeJkh[XO\|YYm=			Ml;MR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNVIh\|ryPLh?=	MkiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh7OE[4NFcoRjF6OUi2PFA4RC:jPh?=
PC6	M1e0[mFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MmfJOkBl[Xm\|	MXLBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFCFNjDj[YxteyClYYLyfYlv\yCyUlOgZYZ1\XJiNjDkZZl{NCCLQ{WwJF0hOC5yMEC0N{DPxE1w	M1[3U\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
HCT116	NYrtNFRwSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MX6zJIRigXN?	M{i4WGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEOg[IF6eyxiSVO1NEA:KDBwMECwOVUh\|ryPLh?=	M2GyclxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
QG56	NIrNb4ZCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NG\nN4k{KGSjeYO=	MkW3RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCTR{W2JINmdGy\|IHHmeIVzKDNiZHH5d{whUUN3MDC9JFAvODB{ODFOwG0v	M2WwUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
NCI-H460	MmKyRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M2LXTFMh\GG7cx?=	NYLpTWo5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjZoTldkA{KGSjeYOsJGlEPTBiPTCwMlAxOzNizszNMi=>	MkLpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NUS4OFMoRjF7MkW0PFQ{RC:jPh?=
BCRP	NVXVNnptSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NG\Sbpg3KGSjeYO=	NVjrdphESW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Yh\XiycnXzd4lv\yCEQ2LQJINmdGy\|IHHmeIVzKDZiZHH5d{whUUN3MDC9JFAvODB3MTFOwG0v	M3;IUVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
KB3-1	M2jpeGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NGmxdpU1KGSjeYO=	MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKG2ndHjv[EwhUUN3MDC9JFAvODB2IN88UU4>	M1Ln[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{CzN\|A3Lz5zOUOwN\|MxPjxxYU6=
KBV1	Ml;6R5l1d3SxeHnjbZR6KGG\|c3H5		MVO0JIRigXN?	M{jIVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KE2GUkGgc5ZmemW6cILld5NqdmdiaIXtZY4hU0KYMTDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIH3leIhw\CxiSVO1NEA:KDBwMES2JO69VS5?	NV;UPVEyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFM{ODZpPkG5N\|A{OzB4PD;hQi=>
KBH5.0	NUGwcmtMS3m2b4TvfIlkcXS7IHHzd4F6		MVy0JIRigXN?	M4r0TGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEKFUmCgc5ZmemW6cILld5NqdmdiaIXtZY4hU0KKNT6wJINmdGy\|IHHmeIVzKDRiZHH5d{BjgSCPVGSgcYV1cG:mLDDJR\|UxKD1iMD6zJO69VS5?	MmLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl\|MEOzNFYoRjF7M{CzN\|A3RC:jPh?=
NCI-H460	NWi5fFVbSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NX\vSGgxOSCqch?=	M4ixVWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTlPJMWg1PjBiY3XscJMh[W[2ZYKgd4hwenRidHXycUBmgHCxc4Xy[UBnd3JiMTDodkBu\WG\|dYLl[EBi\nSncjC3NkBpenNiaX6g[JJ2\y2ocnXlJI1m\Gm3bTygTWM2OCB;IECuNVMh\|ryPLh?=	NXvmTVZvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUm1N\|A4OjBpPkG5OVMxPzJyPD;hQi=>
A549/ATCC	M1XBW2FvfGm2dX3vdkBie3OjeR?=			MUXBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCDNUS5M2FVS0NiY3XscJMh[nliU2LCJI1mfGixZDygTWM2OCB;IECuNFg5KM7:TT6=	MlmwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
HT-29	NUnlVJJCSW62aYT1cY9zKGG\|c3H5			M1\3VGFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjUMVI6KGOnbHzzJIJ6KFOUQjDt[ZRpd2RuIFnDOVAhRSByLkG3JO69VS5?	MoSwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
gastric cancer cells	MVvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		MUW3NkBpenN?	MXfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDnZZN1emmlIHPhcoNmeiClZXzsd{Bi\nSncjC3NkBpenNiYomgd5Vt\m:{aH;kZY1qdmViQjDhd5NigSxiR1m1NEA:KDBwME[2JO69VS5?	Mm\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
lung cancer cells	NVLSO\|hvT3Kxd4ToJIlvcGmkaYTpc44h[XO\|YYm=		NYfDcnBLPzJiaILz	M1zFUmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJIx2dmdiY3HuZ4VzKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDzeYxnd3Kqb3ThcYlv\SCEIHHzd4F6NCCJSUWwJF0hOC5yNk[g{txONg>?	MlntQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
colon cancer cells	MYDHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>?		NGLEcpI4OiCqcoO=	MWXHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUAxNjB4NjFOwG0v	MVu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODh6NEC4PUc,OjB6OESwPFk9N2F-
HT-29	NUPkeY9yS3m2b4TvfIlkcXS7IHHzd4F6			MnfLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMtKEmFNUCgQUAxNjByNUmg{txONg>?	Ml25QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2N{C4OlQoRjJzNEewPFY1RC:jPh?=
A549	MXXDfZRwfG:6aXPpeJkh[XO\|YYm=			M1TaO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMtKEmFNUCgQUAxNjB2NzFOwG0v	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTR5MEi2OEc,OjF2N{C4OlQ9N2F-
PC3	MYHDfZRwfG:6aXPpeJkh[XO\|YYm=		NWTNUlBjPzJiaILz	MX\DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOg[ZhxemW\|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByMk[g{txONg>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjl3OUK0Okc,OjJ7NUmyOFY9N2F-
A2780	M2XWR2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MUK3NkBpenN?	NWn5WpI3S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTJ5OECgZ4VtdHNib4\ldoV5eHKnc4Ppcoch[WyyaHG1ZoV1[TNiaX70[YdzcW5iYYPz[ZN{\WRiYYOgZ4VtdCC\|dYL2bZZidCCjZoTldkA4OiCqcoOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMEmg{txONg>?	MmiwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
DU145	MWLDfZRwfG:6aXPpeJkh[XO\|YYm=			M2jDfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGRWOTR3IHPlcIx{NCCLQ{WwJF0hOC5yMzFOwG0v	NXHKTpE{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1O\|g2PDVpPkKzOVc5PTR3PD;hQi=>
HT-29	MkPSR5l1d3SxeHnjbZR6KGG\|c3H5			MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{whUUN3MDC9JFAvODNizszNMi=>	MXK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzV5OEW0OUc,OjN3N{i1OFU9N2F-
L1210	Mmj1R5l1d3SxeHnjbZR6KGG\|c3H5			NGG5U5lEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBNOTJzMDDj[YxteyxiSVO1NEA:KDBwMESg{txONg>?	NIrJT5A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W3PFU1PSd-MkO1O\|g2PDV:L3G+
DU145	MmfXR5l1d3SxeHnjbZR6KGG\|c3H5		M{LoeFczKGi{cx?=	MoLsR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gSHUyPDViY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBk\WyuII\pZYJqdGm2eTDh[pRmeiB5MjDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMD6xNUDPxE1w	M1\5bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NkKyPVgyLz5{M{[yNlk5OTxxYU6=
DU145	M2PZTmZ2dmO2aX;uJIF{e2G7	M1TPblAvOSC2bzCwMlUhfU1?	M{[wZ\|I1KGi{cx?=	M2PrZmlvcGmkaYTpc44hd2ZiSFTBR{BqdiCqdX3hckBFXTF2NTDj[YxteyCjc4Pld5Nm\CCjczD1dJJm\3WuYYTpc44hd2ZicEKxe4FnOSCneIDy[ZN{cW:wIHH0JFAvOSC2bzCwMlUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdDDhcoFtgXOrcx?=	NGrPRok9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[yNlk5OSd-MkO2NlI6QDF:L3G+
A549	M3vkbWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MUCzJIRigXN?	NV;vR5NFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB\|IHThfZMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNFI4OiEQvF2u	MkTGQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O\|AoRjJ2NUK5PFcxRC:jPh?=
HCT116	Ml\mR5l1d3SxeHnjbZR6KGG\|c3H5		MkTZN{Bl[Xm\|	NXfDU4RIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IEOg[IF6eyCkeTDTVmIh[XO\|YYmsJGlEPTBiPTCwMlA{OSEQvF2u	NEm2So49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HT-29	NH2yTopEgXSxdH;4bYNqfHliYYPzZZk>		M3TyS\|Mh\GG7cx?=	NUfNR\|JCS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiMzDkZZl{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNVA3PjdizszNMi=>	Mn\OQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O\|AoRjJ2NUK5PFcxRC:jPh?=
HCT116	NXfidJZ7S3m2b4TvfIlkcXS7IHHzd4F6			NXfPTXQ6S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUG2JINmdGy\|LDDJR\|UxKD1iMD6xOlYh\|ryPLh?=	NED6eGQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
MDA-MB-231	M4qwPWN6fG:2b4jpZ4l1gSCjc4PhfS=>			NFzYdWhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzMEBKSzVyIE2gNE4yPzZizszNMi=>	NGjYeFQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
A549	MlPQR5l1d3SxeHnjbZR6KGG\|c3H5			MnfLR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{whUUN3MDC9JFAvOjV7IN88UU4>	NHi5Soc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HEK293	M4fONmN6fG:2b4jpZ4l1gSCjc4PhfS=>		NVHCc3FuPzJiaILz	NX;UUHFQUW62cnnud4lkKGO7dH;0c5hq[2m2eTDh[4FqdnO2IFjFT\|I6OyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVe1NEA:KDBwMEC1JO69VS5?	MkfQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV{N{KwOVUoRjJ3MkeyNFU2RC:jPh?=
HCT116	MWfDfZRwfG:6aXPpeJkh[XO\|YYm=		M4rVZ\|czKGi{cx?=	MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVAhRSByLkCwOFI5KM7:TT6=	MYK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUO1PUc,OjV6M{WzOVk9N2F-
HT-29	Ml7FR5l1d3SxeHnjbZR6KGG\|c3H5		NWrPPXJlPzJiaILz	NYm3dIFYS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KHO3bH\vdohw\GGvaX7lJGIh[XO\|YYmsJGlEPTBiPTCwMlAyQDV2IN88UU4>	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh\|NUO1PUc,OjV6M{WzOVk9N2F-
HCT15	NH3pb\|BEgXSxdH;4bYNqfHliYYPzZZk>		NIjObm04OiCqcoO=	NVzvV3A1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFA5KM7:TT6=	M2P1NlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
U251	NHvPUnFEgXSxdH;4bYNqfHliYYPzZZk>		MkDrO\|IhcHK\|	NV\p[XhvS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hXTJ3MTDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNlEh\|ryPLh?=	NILmdnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
U87MG	M3jHcGN6fG:2b4jpZ4l1gSCjc4PhfS=>		NF\6Om84OiCqcoO=	M3LPOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU5P02JIHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCzJO69VS5?	M1nvbVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
HT-29	MVfDfZRwfG:6aXPpeJkh[XO\|YYm=		NGLYN5Y4OiCqcoO=	NUPUOXZ7S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFU1KM7:TT6=	NUWyeGwzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkewOlA4PjBpPkK3NFYxPzZyPD;hQi=>
MCF7	MnOyR5l1d3SxeHnjbZR6KGG\|c3H5		NV20UYhxPzJiaILz	NYWwS2NXS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD61NVUh\|ryPLh?=	M4e1XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5ME[wO\|YxLz5{N{C2NFc3ODxxYU6=
MDA-MB-231	M{fXXGN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2qxTFczKGi{cx?=	M1nDOWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZZN{\XO\|ZXSgZZMh\3Kxd4ToJIlvcGmkaYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFEvQTdizszNMi=>	NHHzZZU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
NCI-H460	MkfmR5l1d3SxeHnjbZR6KGG\|c3H5		NX7IfXluOjRiaILz	NV\5UJpZS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVkOLLVi0OlAh[2WubIOgdJJmfHKnYYTl[EBnd3JiMkSgbJJ{KHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBnd2yub4fl[EBjgSClb33wc5Vv\CC5YYPoc5V1KG2nYYP1doVlKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB3IN88UU4>	M3HSdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
NCI-H460	NXnTdJh2S3m2b4TvfIlkcXS7IHHzd4F6		MmPlNlQhcHK\|	MoewR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IHj5dI95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IECuNFYh\|ryPLh?=	MY[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MEm5O{c,Ojh\|NUC5PVc9N2F-
HT-29	Mmm5R5l1d3SxeHnjbZR6KGG\|c3H5		MVKyOEBpenN?	NX3kdJk1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IH7vdo1wgGmlIHPvcoRqfGmxbjDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCyMlc1KM7:TT6=	MmD1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh\|NUC5PVcoRjJ6M{WwPVk4RC:jPh?=
HT-29	NFrzN49EgXSxdH;4bYNqfHliYYPzZZk>		M17LdFI1KGi{cx?=	MYHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BxemW2cnXheIVlKG[xcjCyOEBpenNidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h\m:ubH;3[YQh[nliY3;tdI92dmRid3HzbI92fCCvZXHzeZJm\CCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOy55MTFOwG0v	M3rv[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6M{WwPVk4Lz5{OEO1NFk6PzxxYU6=
NCI-H460	MnzKR5l1d3SxeHnjbZR6KGG\|c3H5		NEPZdVg4OiCqcoO=	M1HwXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG5EUS2KNE[wJINmdGy\|IHHzd4V{e2WmIHHzJIdzd3e2aDDy[YR2[3Srb36geY5l\XJiaInwc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMES3JO69VS5?	M2XGSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SwOlE{Lz5{OEe0NFYyOzxxYU6=
NCI-H460	MlezR5l1d3SxeHnjbZR6KGG\|c3H5		MWW3NkBpenN?	MkW5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEWg{txONg>?	MlnOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh5NEC2NVMoRjJ6N{SwOlE{RC:jPh?=
HT-29	MVzDfZRwfG:6aXPpeJkh[XO\|YYm=		MmLBO\|IhcHK\|	MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghemWmdXP0bY9vKHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNE4xQTZizszNMi=>	NYHUTHc2RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O\|QxPjF\|PD;hQi=>
HT-29	M3rzfWN6fG:2b4jpZ4l1gSCjc4PhfS=>		MWi3NkBpenN?	M3n2TmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGG\|c3Xzd4VlKGG\|IHfyc5d1cCC{ZXT1Z5Rqd25idX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFAvOTF7IN88UU4>	NVOxOWNpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMki3OFA3OTNpPkK4O\|QxPjF\|PD;hQi=>
TC32	MnHTdWhVWyCjc4PhfS=>			M1;6cJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
A673	MV7xTHRUKGG\|c3H5			NEDENpByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?=	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
DAOY	NU\mdXBKeUiWUzDhd5NigQ>?			M3r6epFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCGQV;ZJINmdGy\|	MkHyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Saos-2	NI[wXo5yUFSVIHHzd4F6			MVPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW2Gxcz2yJINmdGy\|	NUXYS5p6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37	MXTxTHRUKGG\|c3H5			MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	M2LYS5FJXFNiYYPzZZk>			NV;SOWtReUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGLEJINmdGy\|	NEftc2M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MUjxTHRUKGG\|c3H5			NYDQNXpneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uW0hiY3XscJM>	MoHPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-12	MkHSdWhVWyCjc4PhfS=>			M{PBZZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
MG 63 (6-TG R)	NIHuboZyUFSVIHHzd4F6			MkLOdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MoC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	M3q1OJFJXFNiYYPzZZk>			Mk\idWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE6EMU[0N{Bk\Wyucx?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	NX\ibYpteUiWUzDhd5NigQ>?			M2GxPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCRSGOtOVAh[2WubIO=	NXzG[XNSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	NY\P[Y9ieUiWUzDhd5NigQ>?			NH7PSXByUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBDXC1zMjDj[Yxtew>?	NFPJWVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh41	NFv4OodyUFSVIHHzd4F6			Mn3UdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	M2rWVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MWrxTHRUKGG\|c3H5			NY\aNpRxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	MkDJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NWjKeGlweUiWUzDhd5NigQ>?			MlXMdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2VSDDj[Yxtew>?	MmG3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh30	MYDxTHRUKGG\|c3H5			MXjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmh\|MDDj[Yxtew>?	NWPjXmFJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MoLzdWhVWyCjc4PhfS=>			MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	NVixPXdrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh30	M2HyNpFJXFNiYYPzZZk>			M1HES5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	NX3xNGszRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
U-2 OS	MXvxTHRUKGG\|c3H5			MkK0dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	NX7FOpVERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
Rh41	MXnxTHRUKGG\|c3H5			NETGR\|VyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDRzIHPlcIx{	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SJ-GBM2	MU\xTHRUKGG\|c3H5			M4n0UZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	NIHpUnQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NIP1PGRyUFSVIHHzd4F6			MlmxdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tUWMh[2WubIO=	M2frc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB-EBc1	MnvBdWhVWyCjc4PhfS=>			NE\oUYJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
LAN-5	M2DW[pFJXFNiYYPzZZk>			M2XGeZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCOQV6tOUBk\Wyucx?=	NIjsNHE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MYnxTHRUKGG\|c3H5			Ml7hdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN?	NF6yd5I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
HCT116	Mn:wRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		Mnq5O\|IhcHK\|	MVXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR\|UxKD1iMD6wNFA4QCEQvF2u	M3XpOlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMUG1OFkzLz5\|MEGxOVQ6OjxxYU6=
A549	Mkn2RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MUC3NkBpenN?	NIDMPFhCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFAyPjJizszNMi=>	Mke1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzMUW0PVIoRjNyMUG1OFkzRC:jPh?=
MCF7	Mn;DR5l1d3SxeHnjbZR6KGG\|c3H5		NIH3RnQ4OiCqcoO=	NFr5TVFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR\|UxKD1iMD6wNFAyKM7:TT6=	MVW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODF4OUCzPEc,OzBzNkmwN\|g9N2F-
A549	NGTrfHlEgXSxdH;4bYNqfHliYYPzZZk>		NHTyN4k4OiCqcoO=	NE\5T4xEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR\|UxKD1iMD6yJO69VS5?	NVy2WZhYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CxOlkxOzhpPkOwNVY6ODN6PD;hQi=>

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-Chk1 / Chk1 / Topo I ; PubMed: 18509065 Mol Pharmacol Log-phase Ovcar-5 cells were treated for 24 h with diluent (0.1% DMSO, lanes 1 and 6), gemcitabine at 12.5, 25, 50 or 100 nM (lanes 2-5, respectively), or SN-38 at 2.5, 5, 10, 20 and 40 nM in the absence (lanes 7-11) or presence (lanes 12-17) of 50 nM gemcitabine. At the end of the incubation, whole cell lysates were prepared, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with reagents that recognize phospho-Ser345-Chk1, total Chk1, topo I or, as control, β-actin. Because of the limited number of lanes on our electrophoresis apparatus, lanes 1-5 and 6-17 represent two different membranes from the same experiment that were probed simultaneously.	18509065
Growth inhibition assay	Cell viability; PubMed: 25759163 Mol Oncol (A) Drug sensitivity towards SN‐38 and oxaliplatin for the parental and drug resistant cell lines. Cells were exposed to a range of drug concentrations for 48 h and cell viability was assessed by an endpoint MTT assay. Results of representative experiments are shown. Green (triangle) is the parental cell line, blue (diamond) the SN‐38 resistant cell line, and red (square) the oxaliplatin resistant cell line.	25759163

In vivo

After oral dosing, peak SN-38 concentrations occurrs within 1 h, and the The percent unbound SN-38 lactone in murine plasma at 1000 ng/mL is 3.4 +/- 0.67%, whereas at 100 ng/mL the percent unbound is 1.18 +/- 0.14%. SN-38 lactone AUCs in micebearing human neuroblastoma xenografts are greater than in nontumor-bearing animals. ^[2]

Protocol

Kinase Assay:^[1]

- Collapse

Topoisomerase I Assay:

One unit (the minimum amount for full relaxation of 0.5 μg SV40 DNA under the conditions of this study) of topoisomerase I, 0.5 μL of the test compounds, and 0.5μg SV40 DNA are added sequentially to the reaction buffer, which is composed of 25 mM Tris-HCl (pH 7.5), 50 mM KC1, 5 mM MgCl₂, 0.25 mM EDTA disodium salt, 0.25 mM dithiothreitol, 15μg /mL bovine serum albumin, and 5% glycerol. Then, the reaction mixture (50 μL) is incubated for 10 min at 37 °C, and the reaction is terminated by treatment with 7.5 μL of a solution consisting of 1% sodium dodecyl sulfate, 20 mM EDTA disodium salt, and 0.5 mg/mL proteinase K for an additional 30 min at 37°C. The samples are mixed with 5 μL of the loading buffer containing 10 mM Na₂HPO₄, 31.3% sucrose, and 0.3% bromophenol blue. Relaxed (form Ir) DNA is separated from supercoiled (form I) and nicked (form II) DNA by electrophoresis on 0.8% agarose gel at 50 mA and 20 V for 17 h in the presence of 2 μg/mL chloroquine, 10 mM EDTA, 30 mM NaH₂PO₄, and 36 Mm Tris-HCl (pH 7.8). After electrophoresis, the gel is stained with 0.05% ethidium bromide and photographed with UV light (302 nm). The amount of DNA is quantified using a densitometer.

Cell Research:^[3]

- Collapse

Cell lines: A-172, U-87, and LA-567
Concentrations: 0 -1000 nM
Incubation Time: 48 h
Method: MTT assay
(Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	21 mg/mL (53.51 mM)
	Water	Insoluble
	Ethanol	Insoluble

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download SN-38 SDF

Molecular Weight	392.4
Formula	C₂₂H₂₀N₂O₅
CAS No.	86639-52-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NK012
Smiles	CCC1=C2CN3C(=CC4=C(C3=O)COC(=O)C4(CC)O)C2=NC5=C1C=C(C=C5)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04866641	Not yet recruiting	Drug: T-1201 Injection 100 mg Kit	Advanced Solid Tumor	Taivex Therapeutics Corporation	July 5 2021	Phase 1
NCT04617522	Recruiting	Drug: Sacituzumab Govitecan-hziy	Advanced or Metastatic Solid Tumor\|Liver Failure	Gilead Sciences	April 6 2021	Phase 1
NCT03995706	Recruiting	Drug: Sacituzumab Govitecan	Glioblastoma	The University of Texas Health Science Center at San Antonio\|Gilead Sciences	July 17 2019	Early Phase 1
NCT03245450	Completed	Drug: Eribulin mesilate\|Drug: Irinotecan hydrochloride	Refractory or Recurrent Solid Tumors\|Rhabdomyosarcoma\|Non-Rhabdomyosarcoma Soft Tissue Sarcoma\|Ewing Sarcoma	Eisai Inc.	February 22 2018	Phase 1\|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Choose Your Country or Region

By Signaling Pathways

By product type

SN-38